Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News bluebird bio Inc. BLUEV


Primary Symbol: BLUE

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.


Recent & Breaking News (NDAQ:BLUE)

bluebird bio Reports Fiscal Third Quarter 2013 Financial Results

Business Wire November 14, 2013

bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD

Business Wire October 28, 2013

bluebird bio Joins the Russell 2000® Index

Business Wire October 1, 2013

Richard Morgan, Ph.D. Joins bluebird bio as Vice President of Immunotherapy

Business Wire October 1, 2013

Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013

PR Newswire September 6, 2013

bluebird bio to Present at Morgan Stanley Global Healthcare Conference

Business Wire September 4, 2013

bluebird bio Selected As A 2014 Technology Pioneer By The World Economic Forum

Business Wire August 27, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on BLUE, CMRX, CNAT and ICEL

Accesswire August 26, 2013

bluebird bio Reports Fiscal Second Quarter 2013 Financial Results

Business Wire August 14, 2013

bluebird bio to Present at Two Upcoming Conferences

Business Wire August 6, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on AXAS, BLUE, ONXX and TROV

Accesswire July 16, 2013

bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

Business Wire June 24, 2013